Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Ikeda, Yasumasa ^a   Ozono, Iori ^a,b   Tajima, Soichiro ^a   Imao, Mizuki ^a   Horinouchi, Yuya ^a   Izawa Ishizawa, Yuki ^a   Kihira, Yoshitaka ^a   Miyamoto, Licht ^a   Ishizawa, Keisuke ^a   Tsuchiya, Koichiro ^a   Tamaki, Toshiaki ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; DEFEROXAMINE; FERRITIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME REPRESSION; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; INFLAMMATION; IRON CHELATION; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM; MACROPHAGE; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE LEVEL; URETHRA OBSTRUCTION;

ANIMALS; BLOTTING, WESTERN; CHELATION THERAPY; DEFEROXAMINE; FIBROSIS; IMMUNOHISTOCHEMISTRY; IRON CHELATING AGENTS; KIDNEY DISEASES; MICE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; URETERAL OBSTRUCTION;

EID: 84897786390     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089355     Document Type: Article

References (61)

1. Collins AJ, Foley RN, Gilbertson DT, Chen SC (2009) The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol 4 Suppl 1: S5-11.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305.
3. Iwano M, Neilson EG (2004) Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 13: 279-284. (Pubitemid 38582300)
4. Kruszewski M (2003) Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 531: 81-92.
5. Cairo G, Recalcati S, Pietrangelo A, Minotti G (2002) The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic Biol Med 32: 1237-1243. (Pubitemid 34607627)
6. Camaschella C (2005) Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 106: 3710-3717.
7. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, et al. (1994) Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 89: 986-988. (Pubitemid 24201831)
8. Hayashi H, Takikawa T, Nishimura N, Yano M (1995) Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 22: 268-271.
9. Smith MA, Harris PL, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 94: 9866-9868. (Pubitemid 27408156)
10. Liu B, Moloney A, Meehan S, Morris K, Thomas SE, et al. (2011) Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J Biol Chem 286: 4248-4256.
11. Kimura F, Hayashi H, Yano M, Yoshioka K, Matsumura T, et al. (2005) Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C. Hepatogastroenterology 52: 563-566. (Pubitemid 40469468)
12. Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush AI (2000) Metal chelation as a potential therapy for Alzheimer's disease. Ann N Y Acad Sci 920: 292-304. (Pubitemid 32056584)
13. Ishizaka N, Saito K, Mitani H, Yamazaki I, Sata M, et al. (2002) Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. Circulation 106: 1840-1846.
14. Ishizaka N, Saito K, Mori I, Matsuzaki G, Ohno M, et al. (2005) Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats. Arterioscler Thromb Vasc Biol 25: 2282-2288. (Pubitemid 41552643)
15. Naito Y, Hirotani S, Sawada H, Akahori H, Tsujino T, et al. (2011) Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats. Hypertension 57: 497-504.
16. Tajima S, Ikeda Y, Sawada K, Yamano N, Horinouchi Y, et al. (2012) Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Am J Physiol Endocrinol Metab 302: E77-86.
17. Cooksey RC, Jones D, Gabrielsen S, Huang J, Simcox JA, et al. (2010) Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep 2/2) mouse. Am J Physiol Endocrinol Metab 298: E1236-1243.
18. Minamiyama Y, Takemura S, Kodai S, Shinkawa H, Tsukioka T, et al. (2010) Iron restriction improves type 2 diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats. Am J Physiol Endocrinol Metab 298: E1140-1149.
19. Saito K, Ishizaka N, Aizawa T, Sata M, Iso ON, et al. (2004) Role of aberrant iron homeostasis in the upregulation of transforming growth factor-beta1 in the kidney of angiotensin II-induced hypertensive rats. Hypertens Res 27: 599-607. (Pubitemid 39335077)
20. Ishizaka N, Saito K, Furuta K, Matsuzaki G, Koike K, et al. (2007) Angiotensin II-induced regulation of the expression and localization of iron metabolism-related genes in the rat kidney. Hypertens Res 30: 195-202. (Pubitemid 46541794)
21. Naito Y, Fujii A, Sawada H, Hirotani S, Iwasaku T, et al. (2012) Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease. J Hypertens 30: 2192-2201.
22. Naito Y, Fujii A, Sawada H, Hirotani S, Iwasaku T, et al. (2013) Dietary iron restriction prevents further deterioration of renal damage in a chronic kidney disease rat model. J Hypertens 31: 1203-1213.
23. Ikeda Y, Enomoto H, Tajima S, Izawa-Ishizawa Y, Kihira Y, et al. (2013) Dietary iron restriction inhibits progression of diabetic nephropathy in db/db mice. Am J Physiol Renal Physiol 304: F1028-1036.
24. Neufeld EJ (2006) Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 107: 3436-3441.
25. Wang GL, Semenza GL (1993) Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82: 3610-3615. (Pubitemid 24006041)
26. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, et al. (2007) Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117: 3810-3820. (Pubitemid 350224091)
27. Norman JT, Clark IM, Garcia PL (2000) Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 58: 2351-2366.
28. Jung M, Sola A, Hughes J, Kluth DC, Vinuesa E, et al. (2012) Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2. Kidney Int 81: 969-982.
29. Ikeda Y, Tajima S, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, et al. (2012) Estrogen Regulates Hepcidin Expression via GPR30-BMP6-Dependent Signaling in Hepatocytes. PLoS One 7: e40465.
30. Barry M, Flynn DM, Letsky EA, Risdon RA (1974) Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. Br Med J 2: 16-20.
31. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, et al. (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 339: 417-423. (Pubitemid 28377682)
32. Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, et al. (2000) Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 96: 76-79. (Pubitemid 30456453)
33. Yano M, Hayashi H, Wakusawa S, Sanae F, Takikawa T, et al. (2002) Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 97: 133-137. (Pubitemid 34059776)
34. Sartori M, Andorno S, Rigamonti C, Boldorini R (2001) Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig Liver Dis 33: 157-162. (Pubitemid 32294179)
35. Kato J, Kobune M, Nakamura T, Kuroiwa G, Takada K, et al. (2001) Normalization of elevated hepatic 8-hydroxy-29-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 61: 8697-8702. (Pubitemid 34013879)
36. Facchini FS, Hua NW, Stoohs RA (2002) Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 122: 931-939. (Pubitemid 34267276)
37. Saito K, Ishizaka N, Aizawa T, Sata M, Iso-o N, et al. (2005) Iron chelation and a free radical scavenger suppress angiotensin II-induced upregulation of TGF-beta1 in the heart. Am J Physiol Heart Circ Physiol 288: H1836-1843. (Pubitemid 40418011)
38. Massague J (1990) The transforming growth factor-beta family. Annu Rev Cell Biol 6: 597-641.
39. Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169-178.
40. Kaneto H, Morrissey J, Klahr S (1993) Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 44: 313-321. (Pubitemid 23228685)
41. Miyajima A, Chen J, Lawrence C, Ledbetter S, Soslow RA, et al. (2000) Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 58: 2301-2313.
42. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A (2003) Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 112: 1486-1494. (Pubitemid 38056275)
43. Inazaki K, Kanamaru Y, Kojima Y, Sueyoshi N, Okumura K, et al. (2004) Smad3 deficiency attenuates renal fibrosis, inflammation,and apoptosis after unilateral ureteral obstruction. Kidney Int 66: 597-604. (Pubitemid 38982001)
44. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3: 349-363. (Pubitemid 34619269)
45. Alvarez RJ, Sun MJ, Haverty TP, Iozzo RV, Myers JC, et al. (1992) Biosynthetic and proliferative characteristics of tubulointerstitial fibroblasts probed with paracrine cytokines. Kidney Int 41: 14-23.
46. Vielhauer V, Anders HJ, Mack M, Cihak J, Strutz F, et al. (2001) Obstructive nephropathy in the mouse: progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2- and 5-positive leukocytes. J Am Soc Nephrol 12: 1173-1187. (Pubitemid 32472630)
47. Grande MT, Lopez-Novoa JM (2009) Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 5: 319-328.
48. Grgic I, Duffield JS, Humphreys BD (2012) The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 27: 183-193.
49. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, et al. (2004) Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65: 1009-1016. (Pubitemid 38251077)
50. Kawada N, Moriyama T, Ando A, Fukunaga M, Miyata T, et al. (1999) Increased oxidative stress in mouse kidneys with unilateral ureteral obstruction. Kidney Int 56: 1004-1013. (Pubitemid 29411727)
51. Sugiyama H, Kobayashi M, Wang DH, Sunami R, Maeshima Y, et al. (2005) Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant 20: 2670-2680. (Pubitemid 41672265)
52. Li L, Frei B (2006) Iron chelation inhibits NF-kappaB-mediated adhesion molecule expression by inhibiting p22(phox) protein expression and NADPH oxidase activity. Arterioscler Thromb Vasc Biol 26: 2638-2643.
53. Li L, Frei B (2009) Prolonged exposure to LPS increases iron, heme, and p22phox levels and NADPH oxidase activity in human aortic endothelial cells: inhibition by desferrioxamine. Arterioscler Thromb Vasc Biol 29: 732-738.
54. Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, et al. (1999) Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 100: 1494-1498. (Pubitemid 29461459)
55. Fuller SD, Simons K (1986) Transferrin receptor polarity and recycling accuracy in "tight" and "leaky" strains of Madin-Darby canine kidney cells. J Cell Biol 103: 1767-1779. (Pubitemid 17189032)
56. Ferguson CJ, Wareing M, Ward DT, Green R, Smith CP, et al. (2001) Cellular localization of divalent metal transporter DMT-1 in rat kidney. Am J Physiol Renal Physiol 280: F803-814.
57. Canonne-Hergaux F, Gros P (2002) Expression of the iron transporter DMT1 in kidney from normal and anemic mk mice. Kidney Int 62: 147-156. (Pubitemid 34754057)
58. Wolff NA, Liu W, Fenton RA, Lee WK, Thevenod F, et al. (2011) Ferroportin 1 is expressed basolaterally in rat kidney proximal tubule cells and iron excess increases its membrane trafficking. J Cell Mol Med 15: 209-219.
59. Ward DT, Hamilton K, Burnand R, Smith CP, Tomlinson DR, et al. (2005) Altered expression of iron transport proteins in streptozotocin-induced diabetic rat kidney. Biochim Biophys Acta 1740: 79-84. (Pubitemid 40692702)
60. Ferguson CJ, Wareing M, Delannoy M, Fenton R, McLarnon SJ, et al. (2003) Iron handling and gene expression of the divalent metal transporter, DMT1, in the kidney of the anemic Belgrade (b) rat. Kidney Int 64: 1755-1764. (Pubitemid 37323704)
61. Arosio P, Ingrassia R, Cavadini P (2009) Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 1790: 589-599.